Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s.

MLA

Venuto, Charles S., et al. “Raltegravir Pharmacokinetics before and during Treatment with Ombitasvir, Paritaprevir/Ritonavir plus Dasabuvir in Adults with Human Immunodeficiency Virus-1 and Hepatitis C Virus Coinfection: AIDS Clinical Trials Group Sub-Study A5334s.” British Journal of Clinical Pharmacology, vol. 86, no. 1, Jan. 2020, pp. 132–42. EBSCOhost, https://doi.org/10.1111/bcp.14148.

APA

Venuto, C. S., Cramer, Y. S., Rosenkranz, S. L., Sulkowski, M., Wyles, D. L., Cohen, D. E., Schmidt, J., Alston-Smith, B. L., & Morse, G. D. (2020). Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s. British Journal of Clinical Pharmacology, 86(1), 132–142. https://doi.org/10.1111/bcp.14148

Chicago

Venuto, Charles S, Yoninah S Cramer, Susan L Rosenkranz, Mark Sulkowski, David L Wyles, Daniel E Cohen, Jeffrey Schmidt, Beverly L Alston-Smith, and Gene D Morse. 2020. “Raltegravir Pharmacokinetics before and during Treatment with Ombitasvir, Paritaprevir/Ritonavir plus Dasabuvir in Adults with Human Immunodeficiency Virus-1 and Hepatitis C Virus Coinfection: AIDS Clinical Trials Group Sub-Study A5334s.” British Journal of Clinical Pharmacology 86 (1): 132–42. doi:10.1111/bcp.14148.